US Sets Final 10% Section 301 Tariff on Select Indian Imports
The US has imposed a final 10% additional ad valorem duty on select Indian exports, below the 12.5% initially proposed. Pharmaceuticals and smartphones remain exempt, while textile treatment awaits a separate mechanism under India-US trade negotiations.
What happened
Government of India · The US imposed a final 10% Section 301 tariff on select Indian imports, below the proposed 12.5%. Pharmaceuticals and smartphones remain
Key facts
- 10% additional ad valorem duty
- 12.5% initially proposed tariff
- 45% of India's US exports exempt
- 55% of exports subject to duty
- 60 economies covered
- July 23, 2026
Why this matters
Strategic buyers and partners should preserve optionality in India supply-chain, sourcing, and textile deals, as exemptions for pharmaceuticals and smartphones contrast with still-uncertain apparel economics.
What to watch
- Publication of the final Section 301 product list, HTS codes, effective date, exclusion rules, and customs implementation guidance.
- Any India-US announcement establishing a textile or apparel mechanism, including quota treatment, tariff exemptions, reciprocal concessions, or product-specific exclusions.
- Retailer earnings commentary on India sourcing exposure, vendor cost sharing, gross-margin guidance, and apparel/home-textile pricing.
- Indian supplier order-book trends, factory utilization, and quoted FOB price concessions for US buyers.
- Evidence that tariffs expand beyond the initial product coverage or become a negotiating lever in broader US-India trade talks.
- Audit India exposure by SKU, category, supplier, and import date, with particular focus on apparel, home textiles, rugs, leather goods, and private-label seasonal programs.
- Model landed-cost impact under 10%, potential textile-specific rates, and supplier cost-sharing scenarios; identify items where retail price increases would be commercially viable.
- Negotiate temporary vendor allowances, revised Incoterms, and split-country production plans before placing spring and holiday orders.
- Shift marginal new commitments—not necessarily core strategic Indian programs—to alternate qualified factories in Bangladesh, Vietnam, Indonesia, Pakistan, Turkey, and CAFTA markets.
- Review customs classification, origin documentation, and shipment timing to ensure exemptions for pharmaceuticals and smartphones are correctly captured where relevant.